← All trials
NCT02985372
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2016
- Primary completion
- Dec 1, 2018
- Completion date
- Dec 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Shandong UniversityLead sponsor
- Shandong UniversitySponsor investigator
- Shandong UniversityStudy chair
- Linyi People's HospitalCollaborator
- Qingdao UniversityCollaborator
- Shengli Oilfield Central HospitalCollaborator
- Heze Municipal HospitalCollaborator
- People's Hospital of RizhaoCollaborator
- Weihai Municipal HospitalCollaborator
- Nanjing Medical UniversityCollaborator
- Shandong UniversityCollaborator
- Weifang Medical UniversityCollaborator
- Central Hospital, ZiboCollaborator
- Tai'an Central HospitalCollaborator
- Zibo City First HospitalCollaborator
- Taishan Medical UniversityCollaborator
- Binzhou Medical UniversityCollaborator
- People's Liberation Army of ChinaCollaborator
- Shandong Province Qianfoshan HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.